



RECEIVED
CENTRAL FAX CENTER
MAY 26 2004

OFFICIAL

AMYLIN PHARMACEUTICALS, INC.
9373 Towne Centre Drive
San Diego, California 92121 USA
(858) 552-2200
FAX: (858) 552-2212

FAX TRANSMISSION

DATE: 05/26/2004

TO: PTO Central Fax

FAX NO: +1 (703) 872-9306

FROM: Trus, Diane

RE: U.S. Serial No. 09/554,531 - Certificate of Transmission (1 page); Response Under 37 C.F.R. 1.111 (1

Number of pages being transmitted including this sheet: 22

> This communication and any attached documents are for the intended recipient(s) only, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any unauthorized use, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (858-552-2200) or e-mail reply, delete it from your system, and destroy any hard copy you may have printed. Thank you.

>

If you do not receive the entire transmission, please call us immediately.

**RECEIVED
CENTRAL FAX CENTER****MAY 26 2004****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Beeley
Serial No.: 09/554,531
Filed: August 8, 2000
For: NOVEL EXENDIN AGONIST COMPOUNDS
Examiner: Cybille Delacroix-Muirheid

Group Art Unit: 1614
Atty Docket No: 238/087US

OFFICIAL**FACSIMILE TRANSMISSION COVER SHEET****Certificate of Transmission Under 37 C.F.R. 1.8**

I hereby certify that the following listed correspondence in the above referenced application is being transmitted by facsimile to the Commissioner for Patents, Washington DC to telephone number (703) 872-9306 on this 26th day of May, 2004.


Diane Trus

Document	No. of Pages
Response Under 37 C.F.R. 1.111	19
Appointment of Associate Attorney Under 35 U.S.C. 1.34	1

Total Number of Pages Transmitted (including this page)

21

Note: Each paper must have its own certificate of transmission, or this certificate must identify each paper submitted.

09/554,531
Response Under 37 CFR 1.111

Patent
238/087US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nigel R. Beeley
Serial No.: 09/554,531
Filed: August 8, 2000
For: NOVEL EXENDIN AGONIST COMPOUNDS
Examiner: Cybille Delacroix-Muirheid

Group Art Unit: 1614
Confirmation No.: 2006

RESPONSE UNDER 37 C.F.R. 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. 1450
Alexandria, VA 22313-1450

In response to the non-final Office action mailed February 27, 2004, Applicants herewith submit the following amendments and remarks in regard to the above-referenced U.S. patent application.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks begin on page 16 of this paper